1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
2019) In Clinical cancer research : an official journal of the American Association for Cancer Research 25(23). p.7139-7150(
- Contribution to journal › Article
- 2018
-
Mark
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera
(
- Contribution to journal › Article
-
Mark
Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
(
- Contribution to journal › Article
-
Mark
4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
(
- Contribution to journal › Article
-
Mark
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
(
- Contribution to journal › Article
- 2015
-
Mark
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
(
- Contribution to journal › Article
- 2011
-
Mark
PKA-induced phosphorylation of ER alpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer
(
- Contribution to journal › Article
- 2009
-
Mark
Estrogen Receptor-{alpha} Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer.
(
- Contribution to journal › Article